Effects of dapagliflozin on body composition and its relation to hemodynamics in heart failure with preserved ejection fraction: the CAMEO-DAPA randomized clinical trial
Naser J, Tada A, Harada T, Reddy Y, Carter R, Testani J, Jensen M, Borlaug B. Effects of dapagliflozin on body composition and its relation to hemodynamics in heart failure with preserved ejection fraction: the CAMEO-DAPA randomized clinical trial. European Heart Journal 2024, 45: ehae666.1044. DOI: 10.1093/eurheartj/ehae666.1044.Peer-Reviewed Original ResearchPulmonary capillary wedge pressureFat-free massEffects of dapagliflozinDual-energy X-ray absorptiometryBone mineral contentTrunk fatBody compositionCardiac hemodynamicsHeart failureExercise pulmonary capillary wedge pressureTotal body fat-free massHemodynamic effectsBody fatEnergy X-ray absorptiometryReduced fat-free massWeeks of dapagliflozinDevelopment of heart failureBody fat-free massPlacebo-controlled studyFavorable hemodynamic effectsCapillary wedge pressureX-ray absorptiometryPlasma volumeDecreased risk of hospitalizationTotal body fat